Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
November 25, 2022 – Oxipit, AI medical imaging firm, has expanded its high quality product line with high quality assurance help for musculoskeletal X-rays, mammography photographs and lung CT scans. The upgraded high quality suite, which beforehand solely supported chest X-rays, goals to reply all high quality assurance wants of the imaging division with a single product. The up to date high quality product will likely be showcased at RSNA 2022 Annual Meeting later this month.
Oxipit Quality makes use of AI because the second reader for high quality assurance. The product analyzes closing radiologist stories and corresponding medical photographs. If the app detects an unreported clinically important discovering, it notifies the radiologist to look once more. The software in close to real-time operation can stop diagnostic errors earlier than therapy choices are made.
“AI double studying is a transformative drive for diagnostic high quality assurance. Having prevented 1000’s of clinically vital misses throughout lots of of 1000’s of CXR research, along with our clients, we have now constructed a powerful perception in our Quality Framework. With further help for the brand new modalities, we will lengthen this digital security internet to absolutely the majority of the radiology division’s workflow”, says CEO of Oxipit Gediminas Peksys.
According to Gediminas Peksys, this is also a strategic milestone for Oxipit, which previously offered products for chest X-rays only.
“For mainstream adoption, AI medical imaging products must touch the full scope of the radiology department’s work, providing diagnostic quality and productivity improvements. By offering a single point of integration, identical workflow for all imaging modalities, familiar ease of use, AI products can bring tangible benefits to healthcare institutions”, adds Gediminas Peksys.
Along with chest X-rays, musculoskeletal studies make up the vast majority of imaging studies in a typical medical setting. As with chest studies, MSK studies often include subtle fractures that can be easily missed—especially when operating in a time-constrained emergency care setting.
According to Gediminas Peksys, subtle findings are an area where Oxipit Quality excels.
“In the case of chest X-rays, our deployments recommend that synthetic intelligence can considerably advance the identification of refined pulmonary nodules and small infiltrations,” adds Gediminas Peksys.
Oxipit Quality product has also been instrumental in improving early lung cancer diagnostics. The joint trial with AstraZeneca and two primary care centers in Lithuania concluded that Oxipit Quality could identify up to 20% more cases of lung cancer at a much earlier stage.
“With the added help for mammography research, this AI-powered double-reading method can now be utilized in breast most cancers screening,” says Gediminas Peksys.
For extra data: www.oxipit.ai
Find extra RSNA22 protection right here
